James Krainson
Pulmonary Disease · Miami, FLNPI 1174519987
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,517 of the $2,299 with a category attached, or 66.0%. AstraZeneca accounts for 73.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2020 at $1,672 and has fallen 97.8% since, to $37 in 2021. That places this record below the midpoint for pulmonary disease clinicians in FL, where the typical reported total is $2,936.
Across 32 payments — averaging $71.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novartis$255
- GSK$147
- Boehringer Ingelheim$111
- Resmed Corp$37
- Fisher & Paykel Healthcare Inc$35
- plus $15 from 1 others
Across 693 payments — averaging $16,998 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$10.2M
- Pfizer$784K
- AstraZeneca$151K
- Merck$149K
- Eisai Inc.$144K
- Eli Lilly$120K
- plus $245K from 7 others
What the payments were for
- Consulting fees$1,51766%
- Food & beverage$77334%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $1,698 |
| Novartis | 5 | $255 |
| GSK | 9 | $147 |
| Boehringer Ingelheim | 4 | $111 |
| Resmed Corp | 1 | $37 |
| Fisher & Paykel Healthcare Inc | 1 | $35 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,299 in reported general payments places this provider in the 45th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Miami
- Javier Perez FernandezMiami$496K
- Raul ValorMiami$232K
- Shirin ShafazandMiami$193K
- Michael HernandezMiami$153K
- Ignacio CendanMiami$140K
- Andres SosaMiami$91K
- Jaime AvecillasMiami$70K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.